Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 study

Oh, Do‐Youn; P. Algazi, Alain; Capdevila, Jaume; Longo, Federico; H. Miller, Wilson; Tan Chun Bing, Jerry; Bonilla, Carlos; Cheol Chung, Hyun; Kyrre Guren, Tormod; Lin, Chia‐Chi; Motola‐Kuba, Daniel; H. Shah, Manisha; Hadoux, Julien; Yao, Lili; Jin, Fan; Norwood, Kevin; Lebellec, Loïc

doi:10.1002/cncr.34657

Public

Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 study

Published in Cancer • Feb 7, 2023

Authors:

Do‐Youn Oh

Alain P. Algazi

Jaume Capdevila

Abstract

BACKGROUND: The authors report results from the thyroid carcinoma cohort of the multicohort phase 2 KEYNOTE-158 study (NCT02628067), which evaluated pembrolizumab monotherapy in patients with previously treated cancers. METHODS: Eligible patients had histologically and/or cytologically confirmed pap...

Subject

Medicine

Pembrolizumab

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!